NEW YORK, August 14, 2018 /PRNewswire/ -- Pharmaceutical
Drugs Global Market Opportunities And Strategies By the Drugs For
Treatment: Musculoskeletal Disorders Drugs, Cardiovascular Drugs,
Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs,
Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory
Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs,
Dermatology Drugs, Ophthalmology Drugs; With Forecast Until
2021
Read the full report: https://www.reportlinker.com/p05482362
The pharmaceutical industry develops drugs to diagnose, cure, treat
or prevent diseases.Pharmaceutical companies produce both generic
and branded drugs.
Pharmaceutical drugs are subjected to various laws and regulations
that deal with patenting, testing, safety, efficacy and marketing.
Pharmaceutical drugs are intended for human or veterinary use
presented in their finished dosage form.
Executive Summary
The global pharmaceutical drug market was worth $934.8 billion in 2017 and has grown at a CAGR of
5.16% during 2013-2017. The market is expected to grow at a CAGR of
5.78% during 2017-2021 and is forecast to be worth $1,170.4 billion by 2021. Global GDP is expected
to grow significantly to 2021, so the 5.78% annual growth of the
global pharma market does not register in the percentage figures.
Aging populations, income growth especially in emerging economies
and the high prices of new drugs are factors leading to steadily
increasing per capita drugs expenditure.
North America accounted for 36.5%
of the global pharmaceutical drugs market in 2017 and was worth
$341.1 billion. This market share was
primarily due to the better healthcare system, access to high value
drugs, healthcare awareness, high per capita expenditure on
healthcare and high GDP of the region. Asia Pacific was the second largest region
with a share of 21.8% in 2017 and the market was worth $200.8 billion. This was mainly due to the
prevalence of chronic conditions and the large population based of
the region. Western Europe was the
third largest region accounting for $180.9
billion or 19.4% of the market. This market was driven by
increased investment in research and development, aging population,
ability to afford high value drugs and established healthcare
system. South America was the
fourth largest region accounting for $80.9
billion or 8.6% of the market. Rising disposable income,
government healthcare policies and availability of affordable
generic drugs are main drivers of this market. Eastern Europe was fifth largest region
accounting for $60.9 billion or 6.5%
of the market followed by Middle
East with a share of 4.4%, $41.3
billion, and Africa with a
market worth $28.8 billion in
2017.
At the country level, The USA was
the largest country in the pharmaceutical drugs market in 2017,
accounting for $234.7 billion or
25.1% market. The USA's per capita
medical drugs spend has been and will be to 2021 the world's
highest, followed by those of Australia and Germany. China was the second largest country
accounting for $52.6 billion followed
by Japan with a market worth
$43 billion in 2017. Germany was the fourth largest country
accounting for $37 billion in 2017.
Russia was the smallest country
accounting for $12.1 billion and this
can be attributed to the presence of generics and less reliance on
imported pharmaceutical drugs.
As a percentage of GDP in 2013 the USA's drugs expenditure was highest, but by
2017 it had been overtaken by both Brazil and Italy, whose market was worth $29.1 billion and $24.7
billion respectively, and the situation will continue to
2021. In terms of the number of pharmacist, the huge populations of
India and China meant that these countries had the
highest number of pharmacists in 2017. Three of the BRICs,
India, China and Brazil, have low spend on pharma, despite very
high numbers of pharmacists, implying that the drugs revenue per
pharmacist in these countries is relatively low. With more generic
drugs occupying the market, it was observed that 70% of drug sales
in India were generics whereas in
many Western countries it was much lower, for example in
Italy generics made up only 11% of
the market. New drug approvals in 2017 were highest in Brazil, 61, and lowest in the USA, followed by Europe. In part this pattern is explained by
countries approving drugs approved in the USA in earlier years and the slow and
difficult process for new drug approvals in the USA and Europe.
At the global level, pharmaceutical drugs are segmented based on
the therapeutic area with drugs for musculoskeletal disorders as
the largest segment worth $130.2
billion in 2017. Cardiovascular drugs were the second
largest segment followed by oncology drugs with a market worth
$129.6 billion and 125.9 billion
respectively. Ophthalmology Drugs was the smallest major segment in
the pharmaceutical drugs market worth about $27.7 billion.
Description
Where is the largest and fastest growing market for pharmaceutical
drugs? How does the market relate to the overall economy,
demography and other similar markets? What forces will shape the
market going forward? The pharmaceutical drugs global market report
from the Business Research Company answers all these questions and
many more.
The report covers market characteristics, size and growth,
segmentation, regional and country breakdowns, competitive
landscape, market shares, trends and strategies for this market. It
traces the market's historic and forecast market growth by
geography.
• The market characteristics section of the report defines and
explains the market.
• The market size section gives the market size ($b) covering both
the historic growth of the market and forecasting the future.
Drivers and restraints cover the external factors supporting and
controlling the growth of the market.
• PESTLE Analysis covers the political, economic, social,
technological, legal and environmental factors affecting the
pharmaceutical drugs market.
• The customer information section covers major surveys conducted
on the global pharmaceutical drugs market and their
implications.
• Market segmentations break down market into Musculoskeletal
Disorders Drugs, Cardiovascular Drugs, Oncology Drugs,
Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous
System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs,
Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs and
Ophthalmology Drugs. The historic and forecast growth rates for
these segments are also covered in this report. The breakdown of
these segments into sub segments is also covered in this report
• A comparison of the pharmaceutical drugs market with
macro-economic factors and industry metrics is also covered in the
report.
• The regional and country breakdown section gives an analysis of
the market in each geography and the size of the market by
geography and compares their historic and forecast growth. It
covers all the regions, key developed countries and major emerging
markets.
• The competitive landscape section gives a description of the
competitive nature of the market, market shares, and a description
of the leading companies in terms of their offerings, growth
strategy and financial performance.
• The report also covers key mergers and acquisitions in the
pharmaceutical drugs market. Key financial deals which have shaped
the market in recent years are identified.
• The trends and strategies section highlights the likely future
developments in the market and suggests approaches companies can
take to exploit this.
Scope
Markets covered: Musculoskeletal Disorders Drugs, Cardiovascular
Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder
Drugs, Central Nervous System Drugs, Genito-Urinary Drugs,
Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology
Drugs, Dermatology Drugs, Ophthalmology Drugs.
Companies mentioned: Novartis AG, Sanofi S.A., Pfizer Inc. and
Gilead Sciences Inc.
Countries: China, Japan, India,
Australia, USA, Brazil,
UK, Germany, France, Spain, Italy,
Russia, South Africa
Regions: Asia-Pacific,
North America, South America, Western Europe, Eastern Europe, Middle East and Africa.
Time series: Five years historic and forecast.
Data segmentations: country and regional historic and forecast
data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report
is sourced using end notes.
Why this report?
Timely And Critical:
- Early Rx-to-OTC switch
- Increasing demand for new medicines for drug-resistant
infections
- Slow elimination of animal testing in the drug devolopment
equation
- Aggressive changes in some drug prices leading to further
regulation of pricing in the industry
- Increase in the consumption of prescription drugs
- Rising popularity of generic dugs over prescription dugs
Reasons to Purchase
• Outperform competitors using accurate up to date demand-side
dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast
data and the drivers and restraints on the market.
• Create regional and country strategies on the basis of local data
and analysis.
• Stay abreast of the latest customer and market research
findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior
strategizing.
• Suitable for supporting your internal and external presentations
with reliable high quality data and analysis
• Gain a global perspective on the development of the market.
Read the full report: https://www.reportlinker.com/p05482362
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/pharmaceutical-drugs-global-market-opportunities-and-strategies-to-2021-300696809.html
SOURCE Reportlinker